|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- September 23, 2008
CopyrightCOPYRIGHT 2008 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Acacia Pharma Ltd., of Cambridge, UK, initiated its first clinical trial, a Phase I study of its lead product candidate APD 405, being developed for the prevention and treatment of nausea and vomiting after surgery and after treatment with chemotherapy. The trial is a single ascending dose study of the safety, tolerability and pharmacokinetics of APD 405 in healthy volunteers. The study will explore a range of six doses of APD 405 with six volunteers being enrolled at each dose level, one of whom will be randomized to receive a placebo.
ARCA Biopharma Inc., of Broomfield, Colo., said bucindolol, an investigational beta-blocker and mild vasodilator, significantly ...